D

Dynavax Technologies Corp
D

DVAX

15.630
USD
0.04
(0.26%)
مغلق
حجم التداول
0
الربح لكل سهم
1
العائد الربحي
-
P/E
-42
حجم السوق
1,776,881,920
أصول ذات صلة المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.